Baike Biotech Invited to Visit the Chongqing Municipal Center for Disease Prevention and Control, Aimed at Strengthening Strategic Cooperation between the Two Sides
Release time:
2025-10-28
2025 year 10 month 15 On [date], at the invitation of the Chongqing Center for Disease Prevention and Control, Jiang Chunlai, General Manager of Bio-Thera Solutions; Sun Wanfeng, Deputy General Manager; and Shi Nianmin, Director of the Clinical Research Department, together with relevant heads from the Marketing Center, arrived in Chongqing for a one-day exchange visit.
10 month 16 On the morning of [date], accompanied by Yang Zhongping, a member of the Party Committee and Secretary of the Commission for Discipline Inspection at the Chongqing Center for Disease Control and Prevention, Baiker Biotech’s management team, together with relevant representatives from Chongqing Huichang Biological Products Co., Ltd., paid a visit to the Jiulongpo District Center for Disease Prevention and Control. The center is one of the seven vaccine clinical trial sites under the Chongqing CDC.
Xiao Lun, Deputy Secretary of the Party Branch and Director of the Jiulongpo Center for Disease Prevention and Control, led the group on a tour, during which he provided a detailed overview of the center’s development journey and its pivotal role in responding to major public health emergencies.
Zhou Rongxiu, Deputy Director of the Immunization Program Supervision and Management Section of the center, provided a detailed overview of the vaccine clinical trial site’s construction process, organizational structure, project management, and development plan. Meanwhile, Director Xiao shared strategies for overcoming challenges in clinical trial recruitment, offering valuable insights to all attendees.
During the visit to the Chongqing Municipal Center for Disease Control and Prevention, participants were guided and briefed by Li Zhifeng, Deputy Director of the Microbiology Testing Institute. BSL-3 The laboratory and the microbial and viral strain preservation center. During the COVID-19 pandemic, this laboratory successfully isolated the first case of the Delta variant. General Manager Jiang Chunlai expressed high praise for the laboratory’s state-of-the-art equipment, noting that its configuration is already ahead of many university research platforms.
Finally, under the leadership of Zhou Qianru, Deputy Director of the Institute of Physical Chemistry, the group toured the institute’s physicochemical testing laboratory.
In the afternoon, the two sides held a symposium and exchange meeting, which was attended by Zhang Huadong, Deputy Secretary of the Party Committee and Director of the Chongqing Center for Disease Prevention and Control; Yang Zhongping, Member of the Party Committee and Secretary of the Commission for Discipline Inspection; Zhou Chunbei, Deputy Director (in charge of daily operations) of the Institute of Immunization and Disease Prevention; Xu Jiawei, Deputy Director of the Institute; and relevant staff from the Institutional Office.
The meeting was chaired by Secretary Yang Zhongping, with Director Zhang Huadong and General Manager Jiang Chunlai delivering remarks on behalf of their respective sides. Tang Rong, Deputy Director of the Science and Information Division, presented “Chongqing’s Practice in Building a Digital and Intelligent Disease Control System,” during which she noted that, based on “ 1+N+1 “The Intelligent CDC Cloud Platform enables real-time access to patient visit data, thereby establishing “mutual recognition of medical test results.” In the future, it will advance the application of artificial intelligence in the field of disease prevention and control.” + “Digital–intelligence integration is advancing the innovative convergence of artificial intelligence and disease prevention and control.”
Xu Jiawei, Deputy Director of the Institute of Drug Regulation, provided an overview of the vaccine clinical trial base and its development history. 2025 Yearly completion of registration for the Yongchuan, Qijiang, and Nan’an test sites; currently, there are test sites. 7 This has established a networked structure characterized by a “urban core, regional extension, and urban–rural integration,” thereby realizing Chongqing’s leadership in clinical science and upholding the ethical principle of jointly building health.
Next, Cheng Lang, Deputy Director of the Marketing Department at BIC Biotech’s Marketing Center, provided an overview of the company’s development, its current product portfolio, and its R&D pipeline. During the presentation on the R&D pipeline, Dr. Jiang himself delivered a detailed briefing, enabling attendees to gain a deeper understanding of BIC as a company that places great emphasis on research and development.
During the exchange and negotiation session, both sides engaged in lively discussions on future areas and directions for collaboration. Shi Nianmin, Director of the Clinical Research Department at Bio-Thera Solutions, held in-depth consultations and explorations with leaders from the Municipal Center for Disease Control and Prevention regarding the clinical research segment. In addition, Director Zhang extended an invitation to Director Shi to establish an expert panel to conduct simulated inspections of all clinical processes at the Municipal CDC. Further strengthen internal standardization efforts.
Finally, after the two parties reached a preliminary agreement on strategic cooperation, everyone posed for a group photo. This exchange visit has laid a solid foundation for close collaboration between Bio-Thera Solutions and the Chongqing Center for Disease Control and Prevention!
Keywords:
Recommended News